News and Announcements
Read the latest news from the Division of Hematology/Oncology including awards, publications and announcements.
The Robert H. Lurie Comprehensive Cancer Center of Northwestern University has been renewed for a fourth five-year grant, totaling $31.5 million and representing a 36 percent increase over its previous funding.
- 08.13.2018Sheetal Kircher, MD, Medical Director of the Cancer Survivorship Institute at the Lurie Cancer Center, will have the opportunity to shape cancer policy and gain valuable leadership experience as one of the two Health Policy Fellows selected by the American Society of Clinical Oncology (ASCO) for 2018-2019.
The Robert H. Lurie Comprehensive Cancer Center of Northwestern University received the highest rating possible from the National Cancer Institute (NCI), an overall “exceptional,” on the competitive renewal of its Cancer Center Support Grant (CCSG).
The grant award will provide nearly $31.5 million in core funding, a significant increase of 36 percent over the previous award. The CCSG provides essential support for Lurie Cancer Center’s dynamic research programs, as well as infrastructure that includes 14 shared research facilities, resources and technology.
Ali Shilatifard, PhD, has been appointed editor of Science Advances, an open-access journal published by the American Association for the Advancement of Science, which also publishes the journal Science.
Two drugs that target mutations in leukemia showed encouraging results, according to recent clinical trials.
An existing drug significantly lowered the risk of metastasis or death when used in men with non-metastatic castrate-resistant prostate cancer and a rising PSA level, according to a study published in the New England Journal of Medicine.
The presence of cancer cells in the bloodstream of patients with early-stage breast cancer may be predictive of benefit from radiotherapy after surgery, according to a new Northwestern Medicine study.
Northwestern Medicine scientists have discovered an epigenetic imbalance that can lead to cancer, and used these findings to inhibit tumors in models.
The addition of a chemotherapy drug to adjuvant hormone therapy did not improve survival for patients with high-risk prostate cancer, according to a new study.
Patients with advanced prostate cancer who received more intensive treatment experienced worse quality of life at three months, but better overall in the long-term, according to a new Northwestern Medicine study.
Among patients with stage III colon cancer, regular nut consumption was associated with significantly lower rates of cancer recurrence and death, according to a new study.
A new study has found that obese patients with metastatic melanoma live significantly longer than those with a normal body mass index — especially male patients treated with targeted or immune therapy.
Cancer treatment tailored to each unique individual. This is the potential of precision oncology, and the premise of OncoSET.
Maha Hussain, MD, recently published several papers detailing new findings in metastatic castration-resistant prostate cancer treatment and prostate cancer screening.
Dr. Maha Hussain outlines how results from the PROSPER study might impact the treatment landscape for patients with nonmetastatic (M0) prostate cancer that is no longer responding to hormonal therapy, called castration resistant prostate cancer (CRPC).
Even as a growing number of cancer patients are setting up accounts for online access to medical charts, fewer people are actually logging on to look at their test results, a U.S. study suggests.
For the study, researchers examined data on 44,590 cancer patients treated between 2007 and 2016, including 19,434 who set up online MyChart accounts to get remote access to their records.
During this decade, the proportion of patients with MyChart accounts rose from 26 percent to 62 percent, researchers report in JAMA Oncology.
In recent years, however, the number of people checking their test results online declined, from 61 percent in 2012 to 38 percent by the end of the study.
“Exceptional care will never be good enough if we don’t have a cure or impactful treatments for our patients,” says Deputy Director, Maha Hussain, MD. “That’s why my passion is research. Research is what will cure cancer.”
Northwestern Medicine scientists have discovered why Huntington’s disease is so toxic to cancer cells and have harnessed it for a novel approach to treat cancer.
Antibodies that reverse immune system suppression may be able to be used to treat a rare type of melanoma, according to a Northwestern Medicine study published in the journal Nature.
A combination of three therapies was found to provide the greatest benefit to patients with metastatic breast cancer classified as HER2- and hormone receptor-positive, who aren't candidates for chemotherapy, according to a Northwestern Medicine clinical trial.
A device attached to a patient’s scalp that delivers a continuous dose of low-intensity electric fields improves survival and slows the growth of a deadly brain tumor, according to a new trial.
Entrepreneurship has been rapidly expanding at Feinberg. Through a range of initiatives, medical school leadership anticipates that the culture of innovation will only continue to grow in coming years.
Northwestern Medicine scientists have discovered that a protein called BRWD2/PHIP binds to H3K4 methylation, a key molecular event that influences gene expression.
A team of scientists has identified the genetic drivers of diffuse large B-cell lymphoma, the most common type of blood cancer, and determined the genes’ clinical significance.
Small RNA molecules can trigger a mechanism hidden in every cell, forcing it to commit suicide, according to a new Northwestern Medicine study, the first to identify molecules that trigger such a fail-safe mechanism.
Second-year medical students showcased ongoing results from their Area of Scholarly Concentration research projects at a recent poster session.
Northwestern Medicine scientists have discovered surprising findings about an enzyme central to gene expression and mutated in many cancers.
A Northwestern Medicine study found a novel chemical transformation in the formation of colibactin, a toxic agent produced by gut bacteria, including certain strains of E. Coli.
Feinberg — and the University more broadly — is increasingly focused on ensuring that exciting discoveries made by basic scientists are also soon turned into treatments that impact human health.